{"id":"ropinirole-requip","safety":{"commonSideEffects":[{"rate":"30–60","effect":"Nausea"},{"rate":"25–40","effect":"Dizziness"},{"rate":"20–40","effect":"Somnolence"},{"rate":"15–25","effect":"Headache"},{"rate":"10–20","effect":"Orthostatic hypotension"},{"rate":"5–15","effect":"Hallucinations"},{"rate":"5–10","effect":"Syncope"}]},"_chembl":{"chemblId":"CHEMBL1200411","moleculeType":"Small molecule","molecularWeight":"296.84"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ropinirole binds to and activates dopamine D2 and D3 receptors, particularly in the striatum and other basal ganglia structures. By mimicking dopamine's action, it compensates for the dopamine deficiency characteristic of Parkinson's disease, thereby alleviating motor symptoms such as tremor, rigidity, and bradykinesia. It is also used in restless legs syndrome where dopaminergic dysfunction contributes to abnormal sensations and involuntary movements.","oneSentence":"Ropinirole is a dopamine D2/D3 receptor agonist that stimulates dopamine signaling in the brain to improve motor control and reduce tremor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:41.341Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease (motor symptoms)"},{"name":"Restless legs syndrome"}]},"trialDetails":[{"nctId":"NCT02339064","phase":"PHASE3","title":"Infusion of Apomorphine: Long-term Safety Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2015-02","conditions":"Idiopathic Parkinson's Disease","enrollment":99},{"nctId":"NCT02994719","phase":"","title":"Gait Analysis in Neurological Disease","status":"RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2016-03-01","conditions":"Parkinson's Disease, Parkinsonian Disorders, Atypical Parkinson Disease","enrollment":120},{"nctId":"NCT00465452","phase":"PHASE3","title":"Impact of Switching to Continuous Release Dopamine Agonists","status":"COMPLETED","sponsor":"University of Toledo","startDate":"2007-01","conditions":"Parkinson Disease","enrollment":11},{"nctId":"NCT06468371","phase":"NA","title":"Exercise Training Versus Ropinirole in Treating Restless Legs Syndrome Among Hemodialysis Patients","status":"COMPLETED","sponsor":"Lahore General Hospital","startDate":"2022-01-02","conditions":"Hemodialysis, Restless Legs Syndrome, ESRD (End Stage Renal Disease)","enrollment":84},{"nctId":"NCT03038308","phase":"PHASE1, PHASE2","title":"Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole","status":"COMPLETED","sponsor":"Columbia University","startDate":"2016-09-16","conditions":"Hyperprolactinemia, Prolactinoma","enrollment":16},{"nctId":"NCT02138357","phase":"PHASE4","title":"Butrans for Treatment of Restless Legs Syndrome","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2014-04","conditions":"Restless Legs Syndrome","enrollment":""},{"nctId":"NCT03250117","phase":"PHASE1, PHASE2","title":"Relative Bioavailability Study of Ropinirole Implants in Parkinson's Patients on L-Dopa Switched From Oral Ropinirole","status":"TERMINATED","sponsor":"Titan Pharmaceuticals","startDate":"2017-10-10","conditions":"Parkinson Disease","enrollment":6},{"nctId":"NCT03176966","phase":"PHASE4","title":"Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2016-09-02","conditions":"Muscle Cramp, Cirrhosis","enrollment":31},{"nctId":"NCT03806530","phase":"PHASE3","title":"DIalysis Symptom COntrol-Restless Legs Syndrome Trial","status":"COMPLETED","sponsor":"Population Health Research Institute","startDate":"2019-05-01","conditions":"End Stage Renal Disease, Restless Legs Syndrome","enrollment":52},{"nctId":"NCT03708237","phase":"PHASE2","title":"Effectiveness of Ropinirole and Gabapentin for the Treatment of RLS in Patients on Maintenance HD","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2019-02-19","conditions":"Restless Legs Syndrome, End Stage Renal Disease","enrollment":3},{"nctId":"NCT00256854","phase":"PHASE3","title":"Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11-14","conditions":"Restless Legs Syndrome, Restless Legs Syndrome (RLS)","enrollment":135},{"nctId":"NCT00434304","phase":"PHASE2","title":"Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04-09","conditions":"Parkinson Disease","enrollment":62},{"nctId":"NCT00530790","phase":"PHASE2","title":"Clinical Evaluation of Ropinirole CR-RLS ( SK&F101468)Tablets in Restless Legs Syndrome","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08-23","conditions":"Restless Legs Syndrome","enrollment":35},{"nctId":"NCT01536574","phase":"PHASE3","title":"Open-Label Extension Study With REQUIP PR for Subjects From Study ROP111528","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09-02","conditions":"Parkinson Disease","enrollment":295},{"nctId":"NCT00996944","phase":"PHASE2","title":"Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration)","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2009-11-30","conditions":"Restless Legs Syndrome","enrollment":34},{"nctId":"NCT01154166","phase":"PHASE3","title":"A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel Group Study of Six Months Treatment With Ropinirole PR as Adjunctive Therapy in Patients With Parkinson's Disease Who Are Not Optimally Controlled on L-Dopa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-15","conditions":"Parkinson Disease","enrollment":347},{"nctId":"NCT01485172","phase":"PHASE4","title":"A Fixed Dose, Dose Response Study for Ropinirole Prolonged Release in Patients With Early Stage Parkinson's Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01-31","conditions":"Parkinson Disease","enrollment":186},{"nctId":"NCT01929317","phase":"PHASE3","title":"A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2013-08-28","conditions":"Parkinson Disease","enrollment":81},{"nctId":"NCT01494532","phase":"PHASE4","title":"A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04-02","conditions":"Parkinson Disease","enrollment":352},{"nctId":"NCT01435915","phase":"PHASE1","title":"Ropinirole PR Pharmacokinetics Study Among Chinese Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-28","conditions":"Parkinson Disease","enrollment":24},{"nctId":"NCT01371682","phase":"PHASE1","title":"A Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets Manufactured at Crawley and Aranda","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-18","conditions":"Parkinson Disease","enrollment":50},{"nctId":"NCT01393457","phase":"PHASE2","title":"Cognitive Remediation for Cocaine Dependence","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2011-06","conditions":"Cocaine Dependence","enrollment":119},{"nctId":"NCT00674310","phase":"NA","title":"A Single-Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2004-02","conditions":"Parkinson's Disease, Restless Leg Syndrome","enrollment":29},{"nctId":"NCT00673088","phase":"NA","title":"A Single Dose, 2-Period, 2-Treatment, 2-Way Crossover Bioequivalency Study of Ropinirole 0.25 mg Tablets Und Fasted Conditions","status":"COMPLETED","sponsor":"Roxane Laboratories","startDate":"2004-02","conditions":"Parkinson's Disease, Restless Leg Syndrome","enrollment":30},{"nctId":"NCT00419692","phase":"PHASE1","title":"Restless Legs Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole And The Effect Of Food","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08-24","conditions":"Restless Legs Syndrome","enrollment":32},{"nctId":"NCT01327339","phase":"","title":"REQUIP RLS Post Marketing Surveillance","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04-01","conditions":"Restless Legs Syndrome","enrollment":755},{"nctId":"NCT00140712","phase":"PHASE1","title":"Ropinirole Tablets In Young Patients With Restless Legs Syndrome","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-06-10","conditions":"Restless Legs Syndrome","enrollment":9},{"nctId":"NCT00331149","phase":"PHASE3","title":"A Comparison of Ropinirole Immediate Release With Ropinirole Prolonged Release in Patients With Advanced Parkinson's","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06-20","conditions":"Parkinson Disease","enrollment":343},{"nctId":"NCT00051961","phase":"","title":"Effect of Ropinirole on Spinal Cord Reflexes and Restless Legs Syndrome","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2003-01-14","conditions":"Restless Legs Syndrome","enrollment":90},{"nctId":"NCT00282152","phase":"NA","title":"Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD)","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2006-03","conditions":"Parkinson's Disease","enrollment":37},{"nctId":"NCT00314821","phase":"PHASE4","title":"Ropinirole in the Treatment of Bipolar Depression","status":"COMPLETED","sponsor":"Cambridge Health Alliance","startDate":"2005-09","conditions":"Bipolar Disorder","enrollment":40},{"nctId":"NCT00381472","phase":"PHASE3","title":"Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-06","conditions":"Parkinson Disease","enrollment":393},{"nctId":"NCT00632736","phase":"PHASE3","title":"An Open-label Continuation Study Evaluating the Long-term Safety of Extended Release Ropinirole XL (Formerly CR) in Parkinson''s Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-02","conditions":"Parkinson Disease, Parkinson's Disease","enrollment":419},{"nctId":"NCT00329602","phase":"PHASE4","title":"Long-term Study Of Ropinirole In Restless Legs Syndrome","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-03","conditions":"Restless Legs Syndrome","enrollment":404},{"nctId":"NCT00363727","phase":"PHASE3","title":"Onset Motor Complications Using REQUIP CR (Ropinirole Controlled-release) As Add-on Therapy To L-dopa In Parkinson's","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-12","conditions":"Parkinson's Disease, Parkinson Disease, Dyskinesias","enrollment":209},{"nctId":"NCT00823836","phase":"PHASE3","title":"Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03","conditions":"Parkinson Disease","enrollment":302},{"nctId":"NCT01976871","phase":"PHASE4","title":"Switching From Oral Dopamine Agonists to Rotigotine","status":"COMPLETED","sponsor":"John Winkelman, MD, PhD","startDate":"2014-08","conditions":"Restless Legs Syndrome, Ekbom Syndrome, Willis-Ekbom Disease","enrollment":21},{"nctId":"NCT00221390","phase":"PHASE2","title":"Trial of Ropinirole in Motor Recovery After Stroke","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2003-10","conditions":"Cerebrovascular Accident, Hemiparesis","enrollment":52},{"nctId":"NCT00355641","phase":"PHASE3","title":"Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-10","conditions":"Restless Legs Syndrome","enrollment":450},{"nctId":"NCT00460148","phase":"PHASE2","title":"Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04","conditions":"Parkinson Disease","enrollment":28},{"nctId":"NCT00373542","phase":"PHASE4","title":"12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-10","conditions":"Restless Legs Syndrome (RLS), Restless Legs Syndrome","enrollment":39},{"nctId":"NCT00422994","phase":"PHASE1","title":"A Study To Investigate The Effects Of End Stage Renal Disease And Hemodialysis On The Pharmacokinetics Of Ropinirole","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04","conditions":"Restless Legs Syndrome","enrollment":48},{"nctId":"NCT00314860","phase":"PHASE3","title":"RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02","conditions":"Restless Legs Syndrome, Restless Legs Syndrome (RLS)","enrollment":568},{"nctId":"NCT00363857","phase":"PHASE3","title":"A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-08","conditions":"Restless Legs Syndrome (RLS), Restless Legs Syndrome","enrollment":360},{"nctId":"NCT00197080","phase":"PHASE3","title":"Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-06","conditions":"Restless Legs Syndrome","enrollment":380},{"nctId":"NCT00225862","phase":"PHASE3","title":"A Clinical Research Study Evaluating Ropinirole Treatment For Restless Legs Syndrome (RLS)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-01","conditions":"Restless Legs Syndrome","enrollment":140},{"nctId":"NCT00256893","phase":"PHASE2","title":"Fibromyalgia Study In Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-11","conditions":"Fibromyalgia Syndrome, Primary","enrollment":164},{"nctId":"NCT01052831","phase":"PHASE4","title":"Naltrexone for Impulse Control Disorders in Parkinson's Disease","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2009-11","conditions":"Impulse Control Disorder, Parkinson Disease","enrollment":50},{"nctId":"NCT00334048","phase":"PHASE4","title":"Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo","status":"COMPLETED","sponsor":"St. Luke's-Roosevelt Hospital Center","startDate":"2006-06","conditions":"Sexual Dysfunction","enrollment":9},{"nctId":"NCT00593606","phase":"PHASE3","title":"Safety and Tolerability Trial of Switching From Ropinirole to Rotigotine","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2007-07","conditions":"Parkinson's Disease","enrollment":124},{"nctId":"NCT00242008","phase":"PHASE3","title":"A Trial To Assess Switching From Ropinirole, Pramipexole Or Cabergoline To The Rotigotine Transdermal System In Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-12","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT00243971","phase":"PHASE3","title":"A Trial to Compare the Efficacy of Rotigotine Transdermal Patch to That of Ropinirole on Early Morning Motor Impairment and Sleep Disorders in Subjects With Early-Stage, Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-11","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT01723904","phase":"PHASE3","title":"A Phase 3b, Open-Label, Safety and Efficacy Study of Rotigotine as Add-On Therapy With Low Doses of Pramipexole or Ropinirole in Patients With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2012-10","conditions":"Advanced Parkinson's Disease","enrollment":90},{"nctId":"NCT01628926","phase":"PHASE3","title":"A Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","startDate":"2009-06","conditions":"Parkinson's Disease","enrollment":420},{"nctId":"NCT01711866","phase":"PHASE4","title":"A Phase 4, Open-label Study to Assess the Feasibility and Efficacy on Motor and Non-motor Symptoms of Switching From Pramipexole or Ropinirole to Rotigotine Transdermal Patch in Subjects With Advanced Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"UCB BIOSCIENCES GmbH","startDate":"2012-09","conditions":"Advanced Idiopathic Parkinson's Disease","enrollment":87},{"nctId":"NCT00144300","phase":"PHASE4","title":"Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-01","conditions":"Parkinson Disease","enrollment":246},{"nctId":"NCT00605683","phase":"PHASE3","title":"MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2007-11","conditions":"Idiopathic Parkinson's Disease","enrollment":679},{"nctId":"NCT00986245","phase":"PHASE4","title":"Study to Compare the Effect of Ropinirole Prolonged Release Once-daily Versus Twice-daily","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2009-09","conditions":"Parkinson Disease","enrollment":82},{"nctId":"NCT00650104","phase":"PHASE3","title":"Long-term Extension Study Evaluating Extended Release Ropinirole XL (Formerly Referred to as Ropinirole CR) in Patients Who Already Completed Either Study 167 or 164","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-05","conditions":"Parkinson Disease","enrollment":76},{"nctId":"NCT01717235","phase":"PHASE1","title":"Bioequivalence Study of Ropinirole Hydrochloride CR 2mg Tablets of Lupin Limited, India, With REQUIP XL of GlaxoSmithKline Research Triangle Park, in Healthy, Adult, Male, Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Lupin Ltd.","startDate":"2008-09","conditions":"Pharmacokinetic Study","enrollment":12},{"nctId":"NCT01714856","phase":"PHASE1","title":"Bioequivalence Study of Ropinirole Hydrochloride CR 2mg Tablets of Lupin Limited, India, With REQUIP XL of GlaxoSmithKline Research Triangle Park, in Healthy, Adult, Male, Subjects Under Fed Conditions","status":"COMPLETED","sponsor":"Lupin Ltd.","startDate":"2008-09","conditions":"Pharmacokinetic Study","enrollment":12},{"nctId":"NCT01712568","phase":"PHASE1","title":"Two Way Cross Over BE Fasting Pilot Study of Ropinirole Hydrochloride CR 2mg Tablets","status":"COMPLETED","sponsor":"Lupin Ltd.","startDate":"2008-09","conditions":"Pharmacokinetic Study","enrollment":12},{"nctId":"NCT01627834","phase":"PHASE1","title":"Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fasting Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2009-10","conditions":"Healthy","enrollment":48},{"nctId":"NCT01627847","phase":"PHASE1","title":"Bioequivalence Study of Ropinirole Hydrochloride ER Tablets 2 mg Under Fed Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2009-10","conditions":"Healthy","enrollment":48},{"nctId":"NCT00275275","phase":"PHASE3","title":"Pramipexole Conversion to Ropinirole Controlled Release (CR)","status":"COMPLETED","sponsor":"Rajesh Pahwa, MD","startDate":"2006-01","conditions":"Parkinson Disease","enrollment":61},{"nctId":"NCT00305331","phase":"PHASE2","title":"Domperidone as a Treatment for Dopamine Agonist-induced Peripheral Edema in Patients With Parkinson's Disease","status":"TERMINATED","sponsor":"University Health Network, Toronto","startDate":"2006-03","conditions":"Parkinson's Disease, Peripheral Edema","enrollment":25},{"nctId":"NCT00357097","phase":"PHASE3","title":"The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-06","conditions":"Restless Legs Syndrome, Moderate to Severe Idiopathic Restless Legs Syndrome (RLS)","enrollment":240},{"nctId":"NCT01007864","phase":"PHASE3","title":"Influence of Piribedil (Clarium®) on Vigilance and Cognitive Function in Patients With Parkinson's Disease Compared to Other Non-Ergot Dopamine Agonists","status":"COMPLETED","sponsor":"Desitin Arzneimittel GmbH","startDate":"2010-01","conditions":"Idiopathic Parkinson's Disease","enrollment":80},{"nctId":"NCT00367822","phase":"PHASE3","title":"Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)","status":"COMPLETED","sponsor":"Axxonis Pharma AG","startDate":"","conditions":"Restless Legs Syndrome","enrollment":300},{"nctId":"NCT01515774","phase":"PHASE4","title":"Study to Observe the Effect of Mirapex ER® Once-daily (QD) Versus Twice-daily (BID)","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2011-09","conditions":"Parkinson's Disease","enrollment":200},{"nctId":"NCT00344994","phase":"PHASE4","title":"SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole","status":"COMPLETED","sponsor":"Augusta University","startDate":"2006-05","conditions":"Restless Legs Syndrome","enrollment":20},{"nctId":"NCT00399477","phase":"PHASE4","title":"A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease","status":"COMPLETED","sponsor":"Teva Neuroscience, Inc.","startDate":"2006-10","conditions":"Parkinson's Disease","enrollment":200},{"nctId":"NCT00485069","phase":"PHASE4","title":"REQUIP (Ropinirole Hydrochloride) IR Long-Term Phase 4 Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-06","conditions":"Parkinson Disease, Parkinson's Disease","enrollment":123},{"nctId":"NCT00830219","phase":"PHASE1","title":"The Relative Bioavailability Study of Two Ropinirole 0.25 mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-11","conditions":"Healthy","enrollment":46},{"nctId":"NCT00829504","phase":"PHASE1","title":"Ropinirole 0.25 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2004-10","conditions":"Healthy","enrollment":44},{"nctId":"NCT00285727","phase":"NA","title":"Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression","status":"COMPLETED","sponsor":"Stanford University","startDate":"2006-01","conditions":"Depressive Disorder, Major","enrollment":60},{"nctId":"NCT00639119","phase":"PHASE2","title":"Effect of Ropinirole Hydrochloride in Progressive Myoclonic Epilepsy of Unverricht-Lundborg Type","status":"UNKNOWN","sponsor":"University of Turku","startDate":"2007-08","conditions":"Unverricht-Lundborg Syndrome","enrollment":16},{"nctId":"NCT00335205","phase":"PHASE4","title":"A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression.","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2003-04","conditions":"Bipolar Disorder, Major Depressive Disorder","enrollment":60},{"nctId":"NCT00036218","phase":"PHASE3","title":"Study Evaluating Sumanirole for the Treatment of the Signs and Symptoms of Early Parkinson's Disease.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2001-12","conditions":"Parkinson Disease","enrollment":600},{"nctId":"NCT00260793","phase":"PHASE3","title":"Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease","status":"UNKNOWN","sponsor":"Agarwal, Pinky, M.D.","startDate":"2005-11","conditions":"Parkinson's Disease","enrollment":20}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"DIZZINESS"},{"count":3,"reaction":"ARTHRALGIA"},{"count":3,"reaction":"C-REACTIVE PROTEIN INCREASED"},{"count":3,"reaction":"DIARRHOEA"},{"count":3,"reaction":"FATIGUE"},{"count":3,"reaction":"MALAISE"},{"count":3,"reaction":"MUSCLE SPASMS"},{"count":3,"reaction":"NAUSEA"},{"count":3,"reaction":"PAIN"},{"count":3,"reaction":"VOMITING"}],"_approvalHistory":[],"publicationCount":22,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["requip, ropinirole, requip XL"],"phase":"marketed","status":"active","brandName":"Ropinirole (Requip)","genericName":"Ropinirole (Requip)","companyName":"St. Luke's-Roosevelt Hospital Center","companyId":"st-luke-s-roosevelt-hospital-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ropinirole is a dopamine D2/D3 receptor agonist that stimulates dopamine signaling in the brain to improve motor control and reduce tremor. Used for Parkinson's disease (motor symptoms), Restless legs syndrome.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}